Navigation Links
North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017
Date:6/17/2013

DUBLIN, June 17, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9rwvs2/north_america) has announced the addition of the "North America Injectable Drug Delivery Market - by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics- Forecasts to 2017" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self-injection devices.

The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. However, Canada is expected to witness high growth due to growing prevalence of diabetes and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, increase in approval of injectable formulation and device, favorable reimbursement and rise in injectable cosmetic treatments.

This research report categorizes and analyzes the North American injectable drug delivery technologies market under two broad segments - devices and formulations. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Furthermore, due to wide range of applications of injectable drug delivery technologies in varied therapeutic areas, the market is segmented into five categories, namely; auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, Wilson's Disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment).

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Overview

4 Injectable Drug Delivery Devices Technologies Market

5 Injectable Drug Delivery Formulation Technologies Market

6 Injectable Drug Delivery Technologies Market,By Therapeutic Applications

7 Geographic Analysis

8 Competitive Landscape

9 Company Profiles

Companies Mentioned

- Antares Pharma, Inc.
- Baxter International, Inc.
- Becton, Dickinson And Company
- Eli Lilly And Company
- Hospira, Inc.
- Novo Nordisk A/S
- Sanofi
- Unilife Corporation
- West Pharmaceutical Services, Inc.
- Zogenix, Inc.

For more information visit http://www.researchandmarkets.com/research/9rwvs2/north_america

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Delivery


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpace Spotlights Northwests Life Science Community
2. Northwest Bio Implements Major Balance Sheet Clean-Up
3. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
6. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
7. OncoSec to Present at 10th Annual BioPartnering North America
8. Northwest Bio and Fraunhofer IZI Announce Milestones Reached
9. Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America
10. Northeastern University Nanomanufacturing Center Director Ahmed Busnaina to Present Webinar on “The Democratization of Manufacturing”
11. Glythera Relocates to North East as Part of £2M Funding Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... More than $4.3 million was raised last night ... ). The gala was held at the American Museum of ... and honored Alan Alda and P. ... medicine and the public understanding of science. Since the first ... has raised $40 million for the Laboratory,s research and education ...
(Date:12/2/2016)... ... , ... ACEA Biosciences, Inc. announced today that it will be presenting updated ... World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only ... a beautiful technology experience. All three tenets were on display at the 2nd Annual ... from over 40 sponsor, CRO and site organizations to discuss innovation and the future ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
Breaking Biology Technology:
(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil ... corrections and monitoring, announced today that it has offered ... an independent technology judge determine who has the largest ... telephone calling platform, and the best customer service. ... of what we do – which clearly is not ...
Breaking Biology News(10 mins):